In Plain English:
ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the 3D structure of erythropoietin (EPO). Unlike EPO itself, it does not stimulate red blood cell production. Instead it selectively activates the 'Innate Repair Receptor' — a molecular alarm system on damaged and inflamed tissue — triggering anti-apoptotic and anti-inflammatory signaling. Clinical trials show it can regenerate small nerve fibers measurably visible under microscopy, reduce neuropathic pain, and improve metabolic markers in diabetic patients. It is not FDA-approved but holds Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathic pain.
Research Maturity
Phase II Human (60 PubMed papers on ARA-290 / cibinetide; 3 completed Phase 2 RCTs+ Studies)
Focus
Inflammation
Nerve Repair
Neuropathic Pain
Origin
Engineered by Araim Pharmaceuticals from the helical surface of erythropoietin (EPO). The 11-residue sequence (pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) was designed to selectively bind the EPOR/CD131 heteroreceptor complex (Innate Repair Receptor) without stimulating erythropoiesis. First described in peer-reviewed literature in 2012; INN 'cibinetide' assigned by WHO.
Mechanism
Agonist of the Innate Repair Receptor (IRR) — a heteromeric complex of erythropoietin receptor (EPOR) and beta-common receptor (CD131/βcR), selectively upregulated on injured or inflamed tissue. Binding activates JAK2, PI3K-Akt (anti-apoptotic), and MAPK pathways while suppressing pro-inflammatory cytokines (TNF-α, IL-6). Also shown to antagonise TRPV1 nociceptor channels (Zhang 2016, Peptides), providing a direct peripheral pain-relief mechanism independent of systemic immunomodulation. Drives macrophage polarization toward healing phenotype and reduces mast cell degranulation.
Outcome
Phase 2b DOSARA trial (n=64 sarcoidosis): cibinetide 4 mg/day SC × 28 days increased corneal nerve fiber area by 23% vs placebo (p=0.012) and raised GAP-43+ regenerating intraepidermal fibers (p=0.035). Phase 2 diabetic neuropathy trial (n=48): HbA1c fell 0.21% vs +0.21% placebo (p=0.002); PainDetect improved 4.2 vs 0.74 points (p=0.037); corneal nerve fiber density increased 2.6 fibres/mm² in deficient subgroup (p=0.02). Pilot RCT (n=22 sarcoidosis SFN, 2012): SFNSL score Δ −11.5 vs −2.9 placebo (p<0.05).
